Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified a four-gene loop as a non-invasive biomarker that selectively activates in alopecia areata, providing a precise target for JAK inhibitor treatments.

In this study, researchers developed a novel TA-encapsulated microneedle applicator that successfully promoted hair growth and reduced inflammation in a C3H/HeJ mouse model of alopecia areata, potentially offering an improved alternative to existing treatments.

This study utilized targeted genomic sequencing and whole exome sequencing to identify novel common and rare genetic variants in Alopecia Areata, revealing potential mechanisms contributing to disease susceptibility.

This review discusses the classification, diagnosis, and potential treatment pathways for Alopecia Areata, emphasizing the complex genetic and immunological factors involved, but reports no new clinical results.

In this case report, a 28-year-old male with alopecia areata experienced successful hair growth following follicular unit extraction (FUE), with no recurrence observed over a 1-year follow-up.

This study found that abrocitinib showed promising efficacy and safety in adolescents with moderate-to-severe alopecia areata, with significant hair regrowth observed over 10 months of treatment.

This study at Benha University Hospital found that therapies for male androgenetic alopecia are effective and safe based on a randomized trial involving 40 male patients.

This study found that Diphenylcyclopropenone (DCP) was effective for treating extensive alopecia areata in Thai patients, although a high relapse rate suggests maintenance therapy might be necessary.

This study found that intralesional methotrexate and triamcinolone acetonide have similar efficacy for localized alopecia areata in adults, but differ in safety profiles, with methotrexate associated with hyperpigmentation and triamcinolone with atrophy.

Eosinophils are not a reliable marker for diagnosing alopecia areata.

This study found that men with androgenic alopecia had significantly higher levels of lipoprotein (a), a risk factor for coronary artery disease, compared to men with normal hair.

This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.

This editorial proposes a new classification for alopecia areata that incorporates the SALT score and body hair involvement, aiming to improve the assessment and treatment outcomes.

This review examines existing and potential treatments for alopecia areata but does not report new clinical results, emphasizing the need for future therapies that target immune pathways or protect hair follicles from inflammation.

This study introduces ALUDWIG, an automated tool for assessing female androgenic alopecia severity from smartphone images, which may offer a more consistent alternative to current scoring methods like the Ludwig scale.

This study reported that atypical variants of alopecia areata made up less than 25% of all cases in their specialized trichology unit, suggesting a potential selection bias.

This study reports that dupilumab significantly reduced alopecia areata severity in pediatric patients with atopic dermatitis, indicating potential as an effective treatment option, though further research on long-term safety and optimal use is needed.

In this study, eight Chinese patients with alopecia areata showed hair regrowth following combination therapy with a nonablative laser and topical minoxidil, with most patients not experiencing relapse after one year, suggesting a promising alternative treatment without significant side effects.

This review discusses the complex pathogenesis and clinical presentation of Alopecia Areata, highlighting emerging therapies that may offer hope for severe cases but reports no new results.

In this study, researchers identified several active metabolites in Eclipta alba, demonstrated strong interaction with Alzheimer's disease proteins, and found that 28 days of treatment improved memory without significant toxicity in rats, suggesting potential pathways for treating Alzheimer's.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This study reported that 45.5% of patients with beard alopecia areata progressed to scalp alopecia areata within at least 12 months, with most cases occurring during the first year.

This study developed and validated a sensitive liquid chromatography–mass spectrometry method to measure aristolochic acid‐I in rat plasma, successfully applying it to pharmacokinetic research.

This study reported that while various treatments for frontal fibrosing alopecia showed limited effectiveness, dutasteride most effectively stabilized the condition among patients at Duke University.

This study identified a significant genetic association between the TNFα gene and alopecia areata susceptibility in the Jordanian Arab population.

This study found that a bioorthogonal microneedle patch delivering AAV-aFGF effectively improved hair follicle regeneration and sustained hair growth in murine alopecia models compared to other methods.

In this study, researchers characterized alopecia areata incognita in men, finding that all 29 male patients had concurrent androgenetic alopecia, and treatment with ultra-potent topical corticosteroids and minoxidil led to remission in 4-8 months.

Patients and doctors often disagree on alopecia areata severity and treatment satisfaction.

In this triple-blind, randomized clinical trial, researchers found that oral Amla syrup significantly increased the anagen-to-telogen hair ratio and satisfaction levels in women with Female Androgenetic Alopecia compared to placebo, suggesting its potential benefit for treating androgenic hair loss.